Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Carboplatin vs Paclitaxel/Vinorelbine in Advanced NSCLC
NCT00168883Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, paclitaxel and vinorelbine in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Response Rate (Stable Disease or Better) and Safety of the Combination and Life Quality. Status: unknown.
02
Drugs
carboplatinpaclitaxelvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00168883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168883.